collateral growth

collateral growth

formation of vascular bridges between extant arterial networks.
References in periodicals archive ?
Our findings that, in mice, T[eth]4 can promote vessel formation and collateral growth not only during development but also critically from adult epicardium, suggest T[eth]4 has considerable therapeutic potential in humans," stated the researchers.
The aim of this review is to evaluate the interrelations between ADMA and collateral growth.
Scientists at Children's Hospital, Boston, have reported that a growth-promoting molecule known as Inosine stimulated axon collateral growth to an extent never previously shown in an animal model that has many features in common with spinal cord injury in humans.
Rubanyi outlined the current scientific knowledge about the mechanistic basis of adaptive coronary collateral growth, the biological processes that are targeted by therapeutic angiogenesis discoveries and teachings based on Company-sponsored pre-clinical and clinical research, and provided an update on the Generx microvascular gene therapy Phase 3 international clinical study.
Myocardial salvage through coronary collateral growth by granulocyte colony-stimulating factor in chronic coronary artery disease: a controlled randomized trial.
Generx is an angiogenic therapeutic that is designed to promote the heart's natural response of collateral growth and to increase blood flow in the microcirculation.
EECP therapy improves peripheral endothelial function, reduces arterial stiffness and promotes coronary collateral growth
The publication outlines current scientific knowledge about the mechanistic basis of adaptive coronary collateral growth, the biological processes to be targeted by therapeutic angiogenesis, and the optimization of clinical trial designs, including the selection of appropriate clinical trial endpoints, selection of patients who are likely responders to therapeutic stimulation of collateral development, and potential genetic and molecular markers in patient screening.
outlined the current scientific knowledge about the mechanistic basis of adaptive coronary collateral growth, the biological processes to be targeted by therapeutic angiogenesis, and discussed the lessons learned during the past decade of the Company's Generx clinical development program.
The authors evaluated simultaneously the effects of endothelial progenitor cells (EPC) and inflammatory cells on the presence and the extent of coronary artery disease (CAD) and the grade of coronary collateral growth in patients with clinical suspicion of CAD.